Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

DARK SECRETS: 2 | Vintage Vibes

COVID-19 | Covaxin booster dose enhances vaccine effectiveness against Delta, Omicron variants, says ICMR study

New Delhi The administration of Covaxin as a booster dose enhances vaccine effectiveness against COV

The Hindu

US Food and Drug Administration lifts clinical hold, Covaxin trials to resume

HYDERABAD: The US Food and Drug Administration (USFDA) has lifted the clinical hold on the Phase 2 and 3 immuno-bridging clinical trials of Bharat Biotech’s Covid-19 vaccine, Covaxin, in the US.

The Times of India

FDA Removes Clinical Hold On Ocugen's COVID Vaccine Trial

The FDA has lifted the clinical hold on Ocugen Inc's (NASDAQ:OCGN) Phase 2/3 trial, OCU-002, for Covaxin (BBV152), a whole virus inactivated COVID-19 vaccine candidate. In April, the agency paused the trials of the shot, Covaxin, after an inspection of a Bharat Biotech facility by the World Health Organization (WHO) revealed deficiencies…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Bharat Biotech donates ₹1 cr. for Nitya Annadanam for Bhadrachalam temple

BHADRADRI KOTHAGUDEM

The Hindu

Consortium with Bharat Biotech to get $19.3 mn. for ‘futuristic’ jab

Funding is to support development of a ‘variant-proof’ vaccine candidate

The Hindu

COVID-19 situation under control but caution needed with changing virus: V.K. Paul

Country currently has good vaccine coverage, he says

The Hindu

Drugs Controller allows restricted emergency use of Covaxin for 6-12 years

DCGI (Drugs Controller General of India) gives restricted emergency use authorisation to BharatBiotech's Covaxin for children between the age of 6-12 years. More details on Dynamite News:

Dynamite News

Read news from The Economist, FT, and more,
with one subscription

Paving the way for a global malaria vaccine

Malaria impacts India more than anywhere else in southeast Asia, but relief could be on the way if the early promise of vaccines in development is fulfilled.

360info

Why Ocugen Shares Are Trading Higher Today

Ocugen Inc (NASDAQ:OCGN) and Bharat Biotech have amended their co-development, supply, and commercialization agreement to expand Ocugen's exclusive territory to include the commercialization of Covaxin in Mexico. This gives Ocugen Covaxin commercialization rights for all of North America. Covaxin can be an ideal vaccination option for Mexico at this pandemic stage. As a whole…

Benzinga

Morning Digest | Four militants behind J&K targeted killings shot dead; Covaxin trials in U.S. put on hold, and more

A select list of stories to read before you start your day

The Hindu

Covaxin’s Phase 2/3 clinical trials put on hold in the US

HYDERABAD: The US Food and Drug Administration has put on hold the phase 2/3 clinical trials of Bharat Biotech’s Covid-19 vaccine Covaxin in the US.

The Times of India

Covaxin trials in U.S. put on hold

WHO had announced suspension of the vaccine supplies through UN procurement agencies

The Hindu

FDA Places Clinical Hold On Ocugen's Late-Stage COVID-19 Vaccine Trial

The

Benzinga

Price mix-up mars COVID-19 precaution dose roll-out

Some hospitals opt to wait for clarity.

The Hindu

Get all your
news in one place.

100's of premium titles.
One news app.

The Hindu

A pause to reflect: On WHO decision to recommend a pause in the supply of Covaxin

The Government and Bharat Biotech should strive for better communication on vaccine safety

Benzinga

Read Why Did WHO Suspend UN Supply of Bharat Biotech's Covaxin COVID-19 Vaccine

According to Reuters, the World Health Organization suspended the supply of Covaxin through UN agencies for the COVID-19 vaccine. WHO said it would allow the manufacturer to improve its facilities and address issues found in a WHO post-emergency use listing (EUL) inspection of Bharat Biotech's manufacturing. The details of what…

The Hindu

WHO pauses Covaxin supply via UN bodies

Hyderabad

The Times of India

As demand dips, Bharat Biotech slows Covaxin output for maintenance in Hyderabad

HYDERABAD: Bharat Biotech on Friday announced the temporary slowing down of production of its Covid-19 vaccine Covaxin across its manufacturing facilities as it has completed its supply obligations. The company also said that it expected a decrease in demand for the indigenous vaccine.

Get all your
news in one place.

100's of premium titles.
One news app.

The Hindu

Better to err on the side of caution to ensure public health during pandemic, TN tells SC

State says the vaccine mandate, issued through a circular in November last, is backed by law

The Hindu

Vaccination advisory group recommends Covishield second dose eight weeks after first

Government has to take the final call, says National Technical Advisory Group on Immunisation

The Times of India

BB, Biofabri tie up for novel TB vax

HYDERABAD: Bharat Biotech has partnered with Spanish biopharma player Biofabri to develop, manufacture and distribute a novel TB vaccine, MTBVAC, in more than 70 countries with a high TB incidence, primarily in Southeast Asia and sub-Saharan Africa.

Newslaundry

Bharat Biotech defamation case: A day after court order, Wire says no notice yet

Vaccine maker Bharat Biotech has moved court against Wire over at least 14 reports on the company and its vaccine Covaxin in a Rs 100 crore defamation suit, legal news websites reported on Wednesday.

The Hindu

Take down stories on Bharat Biotech, court tells The Wire

The order was pronounced in a ₹100-crore defamation suit the pharmacy giant filed against The Wire

The Times of India

Visakhapatnam: Intranasal Covid vaccine trials at VIMS

VISAKHAPATNAM: The Visakha Institute of Medical Science has got approval to conduct third phase clinical trials of Covid-19 intranasal vaccine. VIMS is the only institution in the state to get an opportunity to conduct the trials. Being developed by Bharat Biotech, the first and second phase trials have already been…

Dynamite News

Bharat Biotech gets DCGI's nod to conduct intranasal booster dose trials

The Drugs Controller General of India (DCGI) on Friday granted permission to Bharat Biotech to conduct clinical trials of intranasal vaccine BBV154.

1 2 3

People

Elon Musk

26,903 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

United Nations

37,049 stories

Bharatiya Janata Party

World Health Organization

885 stories

Food and Drug Administration

337 stories

World Health Organisation

US Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.